Adjuvant therapy for gastric carcinoma patients in the past 15 years

Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites

“…The prognosis of gastric cancer has been improving owing to progress in diagnostic techniques and treatment methods for gastric cancer, but peritoneal dissemination is the main cause of recurrence after curative resection of advanced cancer. The prognosis of gastric cancer which has invaded as far as the gastric serosa is still poor with a 5-year survival of less than 35% (Yamazaki et al, 1989;Shimada and Ajani, 1999). Among these malignant characteristics of gastric cancer cells, metastasis to the peritoneum is an especially complex phenomenon, which requires the involvement of many different genes in multiple steps for tumour cells.…”

Multimodal Therapies for Upper Gastrointestinal Cancers – Past, Now, and Future

“…Complete surgical resection offers the only chance of cure but many cases are presented at advanced stages or recur even after R0 resections. In gastric cancer (GC), 5-year survival rates (SRs) of stages II and III after curative resection range respectively from 30%-49% and 10-20% in Western countries, and respectively 70-80% and 40-50% in Japan and Korea (Fujii et al, 1999;Hundahl et al, 2000; J.P. Kim et al, 1998;Shimada et al, 1999). With regard to esophageal cancer (EC), the 5-year SRs in older series were 14-20% in the United States (Daly et al, 1996;Ries et al, 2007) and ranging from 3 to 11% in European countries, with an average of 10% (Faivre et al, 1998) while they improved to 42% in a recent series (Rice et al, 2009;Ruol A et al, 2009), which is comparable to those (36-46%) after an esophagectomy in Japan (The Japan Esophageal Society).…”

Knockdown of metallopanstimulin‐1 inhibits NF‐κB signaling at different levels: The role of apoptosis induction of gastric cancer cells

“…2 In our previous studies, we used serological analysis of recombinant cDNA expression libraries (SEREX) to define new gastric cancer-related antigens and we successfully identified an array of relevant proteins, including metallopanstimulin-1 (MPS-1), 3 plant homeodomain finger 10 (PHF10) 4 and frizzled-related protein (FRZB).…”

“…1 Although combination therapies are commonly used, the outcome of gastric cancer remains poor as the precise molecular events responsible for its generation and progression are still unknown. 2 In our previous studies, we used serological analysis of recombinant cDNA expression libraries (SEREX) to define new gastric cancer-related antigens and we successfully identified an array of relevant proteins, including metallopanstimulin-1 (MPS-1), 3 plant homeodomain finger 10 (PHF10) 4 and frizzled-related protein (FRZB). 5 The MPS-1 protein, also known as ribosomal protein S27 (RPS27), is a component of the 40S subunit of the ribosome and belongs to the S27E family of ribosomal proteins.…”